The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes

Molecular and Cellular Endocrinology

Volumn 342, Issue 1-2, 2011, Pages 41-47

  Zhang, Y ^a   Lei, T ^a   Huang, J F ^a   Wang, S B ^a   Zhou, L L ^a   Yang, Z Q ^a   Chen, X D ^a  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

FGF21; Hepatocyte; Lipogenesis; Promoter; SREBP1c

Indexed keywords

FATTY ACID; FATTY ACID SYNTHASE; FIBROBLAST GROWTH FACTOR 21; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CELL LEVEL; CELL METABOLISM; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; ESTERIFICATION; FATTY ACID DESATURATION; FATTY ACID TRANSPORT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; LIPID STORAGE; LIPOGENESIS; LIPOPROTEIN SYNTHESIS; LIVER CELL; METABOLIC REGULATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; TRANSCRIPTION REGULATION; UPREGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL LINE; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; LIPOGENESIS; LIVER; MICE; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION, GENETIC; TRIGLYCERIDES;

EID: 79960844094     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.003     Document Type: Article

References (38)

1. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
2. Berglund E.D., Li C.Y., Bina H.A., Lynes S.E., Michael M.D., Shanafelt A.B., Kharitonenkov A., Wasserman D.H. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150:4084-4093.
3. Canbay A., Bechmann L., Gerken G. Lipid metabolism in the liver. Z. Gastroenterol. 2007, 45:35-41.
4. Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., Defronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009, 32:1542-1546.
5. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C., Chen Y., Moller D.E., Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
6. Cuevas-Ramos D., Almeda-Valdes P., Aguilar-Salinas C.A., Cuevas-Ramos G., Cuevas-Sosa A.A., Gomez-Perez F.J. The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism. Curr. Diabetes Rev. 2009, 5:216-220.
7. Dentin R., Girard J., Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 2005, 87:81-86.
8. Dostalova I., Haluzikova D., Haluzik M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol. Res. 2009, 58:1-7.
9. Dushay J., Chui P.C., Gopalakrishnan G.S., Varela-Rey M., Crawley M., Fisher F.M., Badman M.K., Martinez-Chantar M.L., Maratos-Flier E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
10. Ericsson J., Jackson S.M., Lee B.C., Edwards P.A. Sterol regulatory element binding protein binds to a cis element in the promoter of the farnesyl diphosphate synthase gene. Proc. Natl. Acad. Sci. USA 1996, 93:945-950.
11. Febbraio M., Abumrad N.A., Hajjar D.P., Sharma K., Cheng W., Pearce S.F., Silverstein R.L. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 1999, 274:19055-19062.
12. Fisher E.A., Ginsberg H.N. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem. 2002, 277:17377-17380.
13. Fisher F.M., Chui P.C., Antonellis P.J., Bina H.A., Kharitonenkov A., Flier J.S., Maratos-Flier E. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
14. Gao J., Serrero G. Adipose differentiation related protein (ADRP) expressed in transfected COS-7 cells selectively stimulates long chain fatty acid uptake. J. Biol. Chem. 1999, 274:16825-16830.
15. Hijona E., Hijona L., Arenas J.I., Bujanda L. Inflammatory mediators of hepatic steatosis. Mediators Inflamm. 2010, 2010:837419.
16. Iizuka K., Horikawa Y. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr. J. 2008, 55:617-624.
17. Iizuka K., Takeda J., Horikawa Y. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Lett. 2009, 583:2882-2886.
18. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., Elmquist J.K., Gerard R.D., Burgess S.C., Hammer R.E., Mangelsdorf D.J., Kliewer S.A. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
19. Kharitonenkov A., Shanafelt A.B. FGF21: a novel prospect for the treatment of metabolic diseases. Curr. Opin. Investig. Drugs 2009, 10:359-364.
20. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., Gromada J., Brozinick J.T., Hawkins E.D., Wroblewski V.J., Li D.S., Mehrbod F., Jaskunas S.R., Shanafelt A.B. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
21. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., Hansen B.C., Shanafelt A.B., Etgen G.J. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
22. Kliewer S.A., Mangelsdorf D.J. Fibroblast growth factor 21: from pharmacology to physiology. Am. J. Clin. Nutr. 2010, 91:254S-257S.
23. Li H., Fang Q., Gao F., Fan J., Zhou J., Wang X., Zhang H., Pan X., Bao Y., Xiang K., Xu A., Jia W. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J. Hepatol. 2010, 53:934-940.
24. Lopez J.M., Bennett M.K., Sanchez H.B., Rosenfeld J.M., Osborne T.F. Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Proc. Natl. Acad. Sci. USA 1996, 93:1049-1053.
25. Lundasen T., Hunt M.C., Nilsson L.M., Sanyal S., Angelin B., Alexson S.E., Rudling M. PPARalpha is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 2007, 360:437-440.
26. Magana M.M., Osborne T.F. Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter. J. Biol. Chem. 1996, 271:32689-32694.
27. Mai K., Andres J., Biedasek K., Weicht J., Bobbert T., Sabath M., Meinus S., Reinecke F., Mohlig M., Weickert M.O., Clemenz M., Pfeiffer A.F., Kintscher U., Spuler S., Spranger J. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009, 58:1532-1538.
28. Moyers J.S., Shiyanova T.L., Mehrbod F., Dunbar J.D., Noblitt T.W., Otto K.A., Reifel-Miller A., Kharitonenkov A. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J. Cell. Physiol. 2007, 210:1-6.
29. Nguyen P., Leray V., Diez M., Serisier S., Le Bloc'h J., Siliart B., Dumon H. Liver lipid metabolism. J. Anim. Physiol. Anim. Nutr. (Berl.) 2008, 92:272-283.
30. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 2000, 1492:203-206.
31. Poupeau A., Postic C. Cross-regulation of hepatic glucose metabolism via ChREBP and nuclear receptors. Biochim. Biophys. Acta 2011, 1812:995-1006.
32. Ramirez-Zacarias J.L., Castro-Munozledo F., Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil Red O. Histochemistry 1992, 97:493-497.
33. Shimano H. SREBPs: physiology and pathophysiology of the SREBP family. FEBS J. 2009, 276:616-621.
34. Tilg H. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis. Curr. Pharm. Des. 2010, 16:1893-1895.
35. Vallett S.M., Sanchez H.B., Rosenfeld J.M., Osborne T.F. A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene. J. Biol. Chem. 1996, 271:12247-12253.
36. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., Vonderfecht S., Hecht R., Li Y.S., Lindberg R.A., Chen J.L., Jung D.Y., Zhang Z., Ko H.J., Kim J.K., Veniant M.M. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
37. Yabe D., Komuro R., Liang G., Goldstein J.L., Brown M.S. Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc. Natl. Acad. Sci. USA 2003, 100:3155-3160.
38. Yokoyama C., Wang X., Briggs M.R., Admon A., Wu J., Hua X., Goldstein J.L., Brown M.S. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 1993, 75:187-197.